JP2009526849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526849A5 JP2009526849A5 JP2008555299A JP2008555299A JP2009526849A5 JP 2009526849 A5 JP2009526849 A5 JP 2009526849A5 JP 2008555299 A JP2008555299 A JP 2008555299A JP 2008555299 A JP2008555299 A JP 2008555299A JP 2009526849 A5 JP2009526849 A5 JP 2009526849A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- compound
- substituted
- cycloaliphatic
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 57
- 125000001931 aliphatic group Chemical group 0.000 claims 50
- 229910052799 carbon Inorganic materials 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 22
- 125000002950 monocyclic group Chemical group 0.000 claims 22
- 125000005843 halogen group Chemical group 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 229920006395 saturated elastomer Polymers 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 14
- 229940124597 therapeutic agent Drugs 0.000 claims 14
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000004429 atom Chemical group 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102000001253 Protein Kinase Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 108060006633 protein kinase Proteins 0.000 claims 4
- -1 C 3-6 cycloaliphatic Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 150000001409 amidines Chemical class 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000019838 Blood disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 239000003900 neurotrophic factor Substances 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000011278 mitosis Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77299206P | 2006-02-14 | 2006-02-14 | |
| US60/772,992 | 2006-02-14 | ||
| US83137106P | 2006-07-17 | 2006-07-17 | |
| US60/831,371 | 2006-07-17 | ||
| US84935306P | 2006-10-04 | 2006-10-04 | |
| US60/849,353 | 2006-10-04 | ||
| US87620606P | 2006-12-21 | 2006-12-21 | |
| US60/876,206 | 2006-12-21 | ||
| PCT/US2007/003699 WO2007095188A2 (en) | 2006-02-14 | 2007-02-13 | Dihydrodiazepines useful as inhibitors of protein kinases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013009857A Division JP2013067666A (ja) | 2006-02-14 | 2013-01-23 | タンパク質キナーゼの阻害剤として有用なジヒドロジアゼピン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009526849A JP2009526849A (ja) | 2009-07-23 |
| JP2009526849A5 true JP2009526849A5 (https=) | 2010-03-25 |
| JP5243970B2 JP5243970B2 (ja) | 2013-07-24 |
Family
ID=38330249
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008555299A Active JP5243970B2 (ja) | 2006-02-14 | 2007-02-13 | タンパク質キナーゼの阻害剤として有用なジヒドロジアゼピン |
| JP2013009857A Withdrawn JP2013067666A (ja) | 2006-02-14 | 2013-01-23 | タンパク質キナーゼの阻害剤として有用なジヒドロジアゼピン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013009857A Withdrawn JP2013067666A (ja) | 2006-02-14 | 2013-01-23 | タンパク質キナーゼの阻害剤として有用なジヒドロジアゼピン |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7622463B2 (https=) |
| EP (1) | EP1983987B1 (https=) |
| JP (2) | JP5243970B2 (https=) |
| KR (1) | KR20080095902A (https=) |
| AR (1) | AR059505A1 (https=) |
| AT (1) | ATE479434T1 (https=) |
| AU (1) | AU2007215221C1 (https=) |
| CA (1) | CA2652648C (https=) |
| DE (1) | DE602007008837D1 (https=) |
| IL (1) | IL193240A0 (https=) |
| NO (1) | NO20083918L (https=) |
| NZ (1) | NZ570530A (https=) |
| RU (1) | RU2475488C2 (https=) |
| TW (1) | TW200804389A (https=) |
| WO (1) | WO2007095188A2 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| AU2008228303B2 (en) * | 2007-03-22 | 2012-04-19 | Takeda Pharmaceutical Company Limited | Substituted pyrimidodiazepines useful as PLK1 inhibitors |
| TW200914457A (en) * | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
| JP5129812B2 (ja) * | 2007-06-15 | 2013-01-30 | Ｍｓｄ株式会社 | ビシクロアニリン誘導体 |
| AU2008287339A1 (en) * | 2007-08-15 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases |
| EP2205241B1 (en) | 2007-09-25 | 2014-05-21 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| PL2205603T3 (pl) | 2007-09-28 | 2014-07-31 | Cyclacel Ltd | Pochodne pirymidyny jako inhibitory kinaz białkowych |
| US20090291938A1 (en) * | 2007-11-19 | 2009-11-26 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| WO2009071480A2 (en) * | 2007-12-04 | 2009-06-11 | Nerviano Medical Sciences S.R.L. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
| EP2303889A1 (en) | 2008-06-18 | 2011-04-06 | F. Hoffmann-La Roche AG | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| AU2009271658B2 (en) * | 2008-06-23 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors |
| MX2011000021A (es) | 2008-06-23 | 2011-02-24 | Vertex Pharma | Inhibidores de proteina cinasas. |
| RS53347B (sr) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| EP3828185B1 (en) * | 2009-01-06 | 2024-11-20 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| AU2010232644A1 (en) * | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted tetrahydropyrazolo-pyrido-azepin compounds |
| LT3141252T (lt) | 2009-06-17 | 2018-11-12 | Vertex Pharmaceuticals Inc. | Gripo virusų replikacijos inhibitoriai |
| CN102548994A (zh) | 2009-09-25 | 2012-07-04 | 沃泰克斯药物股份有限公司 | 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法 |
| CN103492391A (zh) * | 2009-09-25 | 2014-01-01 | 沃泰克斯药物股份有限公司 | 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法 |
| TW201201813A (en) | 2010-03-31 | 2012-01-16 | Arqule Inc | Substituted benzo-pyrido-triazolo-diazepine compounds |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| EP2571875A4 (en) | 2010-05-14 | 2013-10-30 | Dana Farber Cancer Inst Inc | CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF |
| ES2706066T3 (es) | 2010-07-02 | 2019-03-27 | Univ Health Network | Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas |
| RU2013132681A (ru) | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| WO2014145909A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| JP6618901B2 (ja) | 2013-11-13 | 2019-12-11 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| LT3068776T (lt) | 2013-11-13 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Gripo virusų replikacijos inhibitoriai |
| EP3099677A4 (en) | 2014-01-31 | 2017-07-26 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| CN105940005A (zh) | 2014-01-31 | 2016-09-14 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス，インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
| GB201411581D0 (en) * | 2014-06-30 | 2014-08-13 | Inst Europ Di Oncologia S R L | Compounds inhibiting the enzyme monopolar spindle 1 kinase, pharmaceutical compositions and uses thereof |
| JP6522732B2 (ja) | 2014-07-11 | 2019-05-29 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを治療するためのトール様受容体の調節因子 |
| CN106715437A (zh) | 2014-08-08 | 2017-05-24 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| CN106793775B (zh) | 2014-08-08 | 2020-06-02 | 达纳-法伯癌症研究所股份有限公司 | 二氢碟啶酮衍生物及其用途 |
| SG11201701520TA (en) | 2014-09-16 | 2017-04-27 | Gilead Sciences Inc | Solid forms of a toll-like receptor modulator |
| KR20170068597A (ko) | 2014-10-27 | 2017-06-19 | 텐샤 세러퓨틱스 인코포레이티드 | 브로모도메인 저해제 |
| CN107428747A (zh) | 2014-11-25 | 2017-12-01 | 拜耳制药股份公司 | 取代的吡啶并苯并二氮杂*酮衍生物及其用途 |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| EP3294735B8 (en) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| EP3347021A4 (en) | 2015-09-11 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| TWI810456B (zh) | 2019-05-22 | 2023-08-01 | 美商基利科學股份有限公司 | Tlr7調節化合物及hiv疫苗之組合 |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| KR102734259B1 (ko) | 2021-03-04 | 2024-11-27 | 한양대학교 에리카산학협력단 | 피리디닐 피라졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
| US12552768B2 (en) | 2021-03-04 | 2026-02-17 | Industry-University Cooperation Foundation | Pyridinylpyrazole derivative or pharmaceutically acceptable salt thereof and use thereof |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| KR102696521B1 (ko) | 2021-11-24 | 2024-08-20 | 한양대학교 에리카산학협력단 | 이속사졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5638032B2 (https=) | 1972-08-31 | 1981-09-03 | ||
| US3872122A (en) * | 1973-04-16 | 1975-03-18 | Bristol Myers Co | 11 H-Pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines |
| US3880855A (en) * | 1973-04-16 | 1975-04-29 | Bristol Myers Co | 5,6-DIHYDRO-11-H-pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines |
| JPS51110202A (en) | 1975-03-24 | 1976-09-29 | Susumu Nojima | Denwakyono hyojisochi |
| GB8927872D0 (en) | 1989-12-08 | 1990-02-14 | Beecham Group Plc | Pharmaceuticals |
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US7169778B2 (en) | 1999-09-15 | 2007-01-30 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| MXPA02002938A (es) * | 1999-09-17 | 2004-12-06 | Abbott Gmbh & Co Kg | Inhibidores de cinasa como agentes agentes terapeuticos. |
| US7101869B2 (en) * | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| MXPA02005350A (es) | 1999-11-30 | 2002-12-11 | Pfizer Prod Inc | Compuestos de 2,4-diamino pirimidina utiles como supresores de inmunidad. |
| UA76512C2 (en) | 2001-09-04 | 2006-08-15 | Boehringer Ingelheim Pharma | Dihydropteridinones, a method for producing thereof and use thereof as medicament |
| JP3876265B2 (ja) | 2003-02-26 | 2007-01-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ジヒドロプテリジノン、その製造方法及び薬物形態での使用 |
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| EP2205241B1 (en) | 2007-09-25 | 2014-05-21 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| PL2205603T3 (pl) | 2007-09-28 | 2014-07-31 | Cyclacel Ltd | Pochodne pirymidyny jako inhibitory kinaz białkowych |
| JP4941835B2 (ja) | 2007-09-28 | 2012-05-30 | Ｔｏｔｏ株式会社 | キャビネット及びキャビネットの施工方法 |
| JP5035192B2 (ja) | 2008-09-19 | 2012-09-26 | コニカミノルタアドバンストレイヤー株式会社 | 駆動機構、駆動装置 |
-
2007
- 2007-02-13 US US11/706,070 patent/US7622463B2/en active Active
- 2007-02-13 KR KR1020087022521A patent/KR20080095902A/ko not_active Abandoned
- 2007-02-13 RU RU2008136854/04A patent/RU2475488C2/ru not_active IP Right Cessation
- 2007-02-13 TW TW096105339A patent/TW200804389A/zh unknown
- 2007-02-13 CA CA2652648A patent/CA2652648C/en active Active
- 2007-02-13 NZ NZ570530A patent/NZ570530A/en unknown
- 2007-02-13 AT AT07750530T patent/ATE479434T1/de active
- 2007-02-13 WO PCT/US2007/003699 patent/WO2007095188A2/en not_active Ceased
- 2007-02-13 JP JP2008555299A patent/JP5243970B2/ja active Active
- 2007-02-13 EP EP07750530A patent/EP1983987B1/en active Active
- 2007-02-13 AU AU2007215221A patent/AU2007215221C1/en not_active Ceased
- 2007-02-13 DE DE602007008837T patent/DE602007008837D1/de active Active
- 2007-02-14 AR ARP070100633A patent/AR059505A1/es unknown
-
2008
- 2008-08-05 IL IL193240A patent/IL193240A0/en unknown
- 2008-09-15 NO NO20083918A patent/NO20083918L/no not_active Application Discontinuation
-
2009
- 2009-09-29 US US12/569,237 patent/US8022202B2/en active Active
-
2011
- 2011-08-10 US US13/206,638 patent/US8394952B2/en active Active
-
2013
- 2013-01-21 US US13/745,968 patent/US20140038935A1/en not_active Abandoned
- 2013-01-23 JP JP2013009857A patent/JP2013067666A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526849A5 (https=) | ||
| RU2008136854A (ru) | Дигидродиазепины, которые можно использовать в качестве ингибиторов протеинкиназ | |
| JP2862375B2 (ja) | Ｃｒｆアンタゴニストとしてのピラゾロピリミジン | |
| JP7320595B2 (ja) | インターロイキン－１活性の阻害剤としてのスルホンイミドアミド化合物 | |
| JP2023139195A (ja) | セレブロン（ｃｒｂｎ）に対するリガンド | |
| EP3080131B1 (en) | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| ES2637588T3 (es) | Nuevos compuestos tricíclicos | |
| JP6517928B2 (ja) | キナーゼ阻害剤として有用なインドールカルボキシアミド | |
| JP2010513285A5 (https=) | ||
| JP2022542396A (ja) | Ｃｄ３８の阻害剤としてのヘテロ二環式アミド | |
| JP2018008996A (ja) | ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド | |
| JP2010532381A5 (https=) | ||
| TW201808936A (zh) | 吡咯并苯并二氮呯類及其共軛物 | |
| SI9620103A (sl) | Pirolopirimidini in postopki za njihovo pripravo | |
| US7211669B2 (en) | Imidazolyl derivatives as corticotropin releasing factor inhibitors | |
| JP2000516961A (ja) | 非古典的ピロロ［２，３―ｄ］ピリミジン抗葉酸物質 | |
| KR20090106604A (ko) | 축합 피리딘 화합물 | |
| CA2392584A1 (en) | Substituted pyridazines having cytokine inhibitory activity | |
| JP2008523033A (ja) | ２，４（４，６）ピリミジン誘導体 | |
| CN117143107A (zh) | 1,2-二氢吡啶类衍生物及其制备方法和用途 | |
| CN114096532B (zh) | 抑制酪氨酸激酶2活性的杂环化合物 | |
| CN113773335A (zh) | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 | |
| CN113747894B (zh) | 成纤维细胞生长因子受体2(fgfr2)的降解剂 | |
| RU2008106949A (ru) | Бензимидазолы применимые в качестве ингибиторов протеинкиназ | |
| JP2009502921A5 (https=) |